Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. - Wikidata - wikimedia - TriplyDB

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer.

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer.

http://www.wikidata.org/entity/Q37381579

about

Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic options Profile of neratinib and its potential in the treatment of breast cancer Regulation of ERBB3/HER3 signaling in cancer Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer.Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.Targeted Delivery of Deoxycytidine Kinase to Her2-Positive Cells Enhances the Efficacy of the Nucleoside Analog Fludarabine Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials.Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer.Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence Suppression of tumor angiogenesis by metformin treatment via a mechanism linked to targeting of HER2/HIF-1α/VEGF secretion axis Ethacrynic acid improves the antitumor effects of irreversible epidermal growth factor receptor tyrosine kinase inhibitors in breast cancer.Potential of antibody-drug conjugates and novel therapeutics in breast cancer management.Therapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic.HER2-family signalling mechanisms, clinical implications and targeting in breast cancer.The role of neratinib in HER2-driven breast cancer.Neratinib for the treatment of HER2-positive early stage breast cancer.Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo.Methods of selecting combination therapy for colorectal cancer patients: a patent evaluation of US20160025730A1.Investigational ErbB-2 tyrosine kinase inhibitors for the treatment of breast cancer.In vitro and in vivo studies of the combination of IGF1R inhibitor figitumumab (CP-751,871) with HER2 inhibitors trastuzumab and neratinib.Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.Early clinical development of epidermal growth factor receptor targeted therapy in breast cancer.New protein kinase inhibitors in breast cancer: afatinib and neratinib.The addition of calcitriol or its synthetic analog EB1089 to lapatinib and neratinib treatment inhibits cell growth and promotes apoptosis in breast cancer cells.N-Acetylcysteine breaks resistance to trastuzumab caused by MUC4 overexpression in human HER2 positive BC-bearing nude mice monitored by 89Zr-Trastuzumab and 18F-FDG PET imaging Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host.Co-targeting the HER and IGF/insulin receptor axis in breast cancer, with triple targeting with endocrine therapy for hormone-sensitive disease.The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.Neratinib: First Global Approval.Regulation of dual specificity phosphatases in breast cancer during initial treatment with Herceptin: a Boolean model analysis.The Conundrum of Adjuvant HER2 Treatment Options.Current and Emerging Therapies for HER2-Positive Women With Metastatic Breast Cancer.Novel treatment strategies for patients with HER2-positive breast cancer who do not benefit from current targeted therapy drugs Breast cancer brain metastasis: molecular mechanisms and directions for treatment

P2860

Q26777681-90827964-4B01-4A70-8CD6-B0269E94BC02 Q27012540-D6B2A08B-3C5E-45E3-9182-5CAE5CBB95E1 Q27024334-295B2BD3-06D8-466B-91E5-9860FCF28F91 Q27853060-621E86E2-F0EB-4E6E-B108-ABCBEDBEB057 Q27853122-E015CC7E-A761-473B-B8B8-57AA5BF750AB Q28550176-3E234181-97F4-4118-B488-3374AE7DB99A Q30857631-CF759E9F-8BE6-40D7-A433-550EFA9EB203 Q33822560-F383479C-4A69-4CE5-A063-EB2857572A6C Q34334333-4922A116-C70F-4A75-AA1D-ED50E46A7920 Q35742383-7FCA0D7D-8774-4E50-AA57-2843850E1A14 Q36250585-F46327DA-7C6F-4C26-A82C-CE87DDF1650A Q36689047-D39108FB-2032-4107-A753-383E6FABDFE2 Q37628975-389C50FE-01D4-4F84-9DE9-10260AB6A0A1 Q37671599-C5C0B0C2-4AB9-4699-B6C7-4E590CCC6B62 Q38214802-6067F619-0F90-4313-B3FA-B0B6BBE954EF Q38301236-7BB07272-607D-4D8D-9EDE-6C6412A3FF3A Q38664492-75BB6E19-D61D-4CF4-BC6C-DD070C8406C7 Q38666768-12206FAD-E3E0-4656-9240-C17F04B515DE Q38708134-F6D3591D-B9D2-4DA8-8222-A2C0F4675C30 Q38709385-CAE149A2-DCBF-4794-91B9-DD9141B71657 Q38728508-9C321B4D-481F-48A1-BCCC-4C8B6FBB553C Q38850952-33B191BC-6C92-4384-9743-B3CD2692BA7F Q38861026-993B4974-4020-4094-842D-EC2CFA82C35E Q39167876-AB357323-BE06-4C0A-9C3E-22AE322F070E Q39200319-9715DE79-A89C-4299-8A67-7998E77238EC Q41098254-E21461F9-BDF4-40D5-9016-396A41EB0958 Q41347430-AB16DF64-37F8-4884-AD42-CF2AF01FC463 Q48102534-3D09612E-1D50-49AC-B350-E510404D8EFC Q48195377-946AB4A3-7BFE-44FB-9C50-442F19042D86 Q50187396-2C51910E-6492-4419-9A16-B50ADF999875 Q50201250-CE19BFBC-1752-467B-939C-6A2C98420809 Q52578585-9DC7CD05-D44D-4BEB-9A1C-7193962ED1A7 Q55216913-BAE28A89-B5A0-40AF-911A-2EC08BA64D9E Q55386607-00DAB90E-D7F4-43CE-8A47-5F9665941175 Q57106864-AE46E322-8AC8-4BF8-9E89-BE2FCD044712 Q57291657-07ADD6AE-D348-49CB-9B57-619C2D4CFEE2

P2860

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer.

http://www.wikidata.org/entity/Q37381579

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer.

@en

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer.

@nl

type

label

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer.

@en

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer.

@nl

prefLabel

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer.

@en

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer.

@nl

P1433

Q37381579-524D7AC8-7CCF-4DF9-BBC5-38707DB944BA

P1476

Q37381579-63FF91CE-D188-4ECD-9CAE-15606CFF490C

P2093

Q37381579-1C69B6FF-5E44-4F76-849C-5EE136E2B661

Q37381579-2C58BE29-6993-4EFC-84A3-B36620F3CAE8

Q37381579-3D1FE623-20A8-4AC3-AA14-C2045FEC03D1

Q37381579-3F2331C6-80E6-46DA-AA4A-44945867C228

Q37381579-61F61BB3-CF04-4E5D-979D-2AE6DF6BC4E1

Q37381579-626207B9-3585-4052-9DEF-3719F581EBD3

Q37381579-793CD939-F127-436C-9EF0-2787CEF1172D

Q37381579-8C1D4C90-FB70-482B-9A0A-0C2FAF307378

Q37381579-8D1242A2-5C99-41BB-BB31-BFF398D69299

Q37381579-9019B85B-793E-4595-BE75-2273EBBE36BD

P2860

Q37381579-0EEC5479-E0AF-492F-B638-E1F30826B4B4

Q37381579-315F293F-FD62-4999-8192-3D497B65A7FD

Q37381579-38570A23-3825-4CB7-B271-2843CBC59AEE

Q37381579-39AF8050-5E63-4B82-A4B0-BEFF4358420F

Q37381579-39C19D5C-D482-4359-B76E-130177A2CE3A

Q37381579-3A3C0E82-A864-42B8-807D-6F34C4A4A1F9

Q37381579-3D321573-A1A1-4B4D-9BD1-5D27C68007A3

Q37381579-489EB3A8-1DE2-45A9-ADB9-4BB175C31F7D

Q37381579-56D74D80-F07C-446C-817F-3C58060C2A40

Q37381579-5B06E79F-2913-44D4-8EBC-50A04CC34D2F

P304

Q37381579-2398CE67-C68A-48CD-867A-00BAC454FBCA

P31

Q37381579-7EB3E178-8158-4E86-BFF5-848B68EBA041

P356

Q37381579-5FACF69E-0C3F-40F6-BEEA-C6201C3651F5

P407

Q37381579-A41F0632-BD19-4C33-AB8E-D8CF911A40A4

P433

Q37381579-C373746F-EE49-4438-9A2B-5CABBE2EC351

P478

Q37381579-A37FF44C-FC3E-4ADF-BF0D-CFA54A628CC6

P50

Q37381579-80191CE0-BB1D-4E9C-BB91-D573262D2B42

Q37381579-820DD193-F9CF-4467-82C8-39F0564EB17E

P577

Q37381579-60506246-DD5F-4C3A-9A3D-BE41819E5011

P698

Q37381579-7633B48A-CB47-43D0-85B9-793EF3DA8328

P932

Q37381579-7BACB9AF-A466-4A55-8DF9-39A6FEA6CD48

P356

ONCOTARGET.1148

P1433

P1476

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer.

@en

P2093

Alexandra Canonici

http://www.w3.org/2001/XMLSchema#string

Anthony Kong

http://www.w3.org/2001/XMLSchema#string

Dennis Siamon

http://www.w3.org/2001/XMLSchema#string

Esther Bridge

http://www.w3.org/2001/XMLSchema#string

Ioannis Roxanis

http://www.w3.org/2001/XMLSchema#string

Ji-Liang Li

http://www.w3.org/2001/XMLSchema#string

John Crown

http://www.w3.org/2001/XMLSchema#string

Kasper Pedersen

http://www.w3.org/2001/XMLSchema#string

Merel Gijsen

http://www.w3.org/2001/XMLSchema#string

Michael J Duffy

http://www.w3.org/2001/XMLSchema#string

P2860

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

Activating HER2 mutations in HER2 gene amplification negative breast cancer

P304

1592-1605

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.1148

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Norma O'Donovan

P577

2013-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24009064

http://www.w3.org/2001/XMLSchema#string

P932

3858548

http://www.w3.org/2001/XMLSchema#string